<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909294</url>
  </required_header>
  <id_info>
    <org_study_id>STEREO-RML</org_study_id>
    <nct_id>NCT04909294</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma</brief_title>
  <acronym>STEREO-RML</acronym>
  <official_title>Multicenter Phase II Study Evaluating the Efficacy and Safety of a Stereotaxic Prostatic Radiotherapy Delivered on Linac MRI, With Integrated Boost in the Case of an Index Tumor, in Patients With Prostate Adenocarcinoma of Favorable, Intermediate or Risky Risk. High Risk Very Localized.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotaxic prostatic radiotherapy on Linac MRI, with monitoring of movements of the pelvic&#xD;
      organs per fraction on the prostate in real time, in 4 sessions, with integrated boost on the&#xD;
      index tumor (if it is visible on the diagnostic MRI), could reduce the digestive, urinary and&#xD;
      sexual toxicities accumulated at 5 years and guarantee excellent local tumor control, for&#xD;
      patients with localized prostate cancer, with a favorable prognosis, intermediate or very&#xD;
      local high risk, according to the D'Amico classification.&#xD;
&#xD;
      The benefits that patients participating in this research could obtain are:&#xD;
&#xD;
        -  Better disease control efficiency&#xD;
&#xD;
        -  A reduction in the duration of treatment to 4 radiotherapy sessions (2 weeks maximum)&#xD;
           instead of 40 sessions (8 weeks) for usual treatment.&#xD;
&#xD;
        -  Avoid the risks associated with the implantation of prostate markers necessary for&#xD;
           stereotaxic radiotherapy on a standard accelerator (anesthetic risks, infectious risks,&#xD;
           hemorrhagic risks, pain risks)&#xD;
&#xD;
        -  Better quality of life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late gastrointestinal and urinary toxicity grade ≥ 2</measure>
    <time_frame>5 years</time_frame>
    <description>toxicities graded according to the NCI-CTCAE-V5.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>stereotaxic external radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiotherapy with Linac MRI</intervention_name>
    <description>38 Gy in 4 fractions of 9.5 Gy over the entire prostate,&#xD;
+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI.</description>
    <arm_group_label>stereotaxic external radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. prostate adenocarcinoma&#xD;
&#xD;
          2. WHO performance index ≤ 1&#xD;
&#xD;
          3. Patient presenting one of the following cases:&#xD;
&#xD;
               -  Low risk: ≤ T2a and Gleason 6 (3 + 3) and PSA &lt;10 ng / ml&#xD;
&#xD;
               -  Intermediate risk: T2b-T2c or Gleason 7 or PSA &lt;15 ng / ml&#xD;
&#xD;
               -  High localized risk: T3a and Gleason ≤7 and PSA &lt;15 ng / ml&#xD;
&#xD;
          4. Disease presenting a risk of lymph node involvement &lt;15%&#xD;
&#xD;
          5. Absence of pelvic or lumbar aortic lymphadenopathy&#xD;
&#xD;
          6. Absence of bone or visceral metastasis&#xD;
&#xD;
          7. IPSS score &lt;15 or ≤ 7&#xD;
&#xD;
          8. Prostate volume estimated by MRI or ultrasound &lt; 90cc&#xD;
&#xD;
          9. If hormonotherapy, hormone therapy must not have started for more than 60 days before&#xD;
             inclusion.&#xD;
&#xD;
         10. Absence of prior pelvic radiotherapy&#xD;
&#xD;
         11. No surgical treatment for prostate cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prostate cancer of histology other than adenocarcinoma&#xD;
&#xD;
          2. Contraindication to MRI including, but not limited to, patients with a pacemaker or&#xD;
             defibrillator&#xD;
&#xD;
          3. Patient diagnosed N1 during imaging workup or pN1&#xD;
&#xD;
          4. Serum PSA level ≥ 15 ng / ml&#xD;
&#xD;
          5. IPSS score ≥ 15 or IPSS score&gt; 7 if alpha blocking urological treatment in progress&#xD;
&#xD;
          6. Prostate volume estimated on MRI or ultrasound&gt; 90 cc&#xD;
&#xD;
          7. Involvement of seminal vesicles on MRI&#xD;
&#xD;
          8. History of cancer in the 5 years preceding entry into the trial&#xD;
&#xD;
          9. History of transurethral resection of the prostate less than 6 months compared to the&#xD;
             expected date of start of radiotherapy&#xD;
&#xD;
         10. rectal surgery&#xD;
&#xD;
         11. pelvic irradiation&#xD;
&#xD;
         12. Patient treated with antineoplastic or medication which may include Methotrexate&#xD;
&#xD;
         13. Hormone therapy started for more than 60 days at the time of inclusion&#xD;
&#xD;
         14. Severe uncontrolled hypertension&#xD;
&#xD;
         15. Patient followed or treated for severe or unstable angina, or having presented a&#xD;
             myocardial infarction in the 6 months preceding the randomization&#xD;
&#xD;
         16. Patient on immunosuppressant&#xD;
&#xD;
         17. Patient with known hypersensitivity to gadoteric acid, meglumine or any drug&#xD;
             containing gadolinium&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magali QUIVRIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

